← Leaderboards
Andrew D. Nguyen
J. David Gladstone Institutes
$3,691,715
Attributed
$3,900,027
Total exposure
7
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $908.6K · FY2012–24$1M$750K$500K$250K$0
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$3,900,027 · 7
By mechanism
R01$1,890,403 · 1
R21$833,250 · 2
R00$728,423 · 1
K99$256,824 · 1
F32$115,777 · 1
R56$75,350 · 1
Top collaborators
- Andrew Alistair Butler1 shared
Most similar at J. David Gladstone Institutes
Same institution · by research overlap
- Steven M Finkbeiner$50,309,699
- Yadong Huang$44,833,692
- Stephen G Young$51,231,576
Others in their field
Top investigators on “Proteins”
- David Heimbrook · Leidos Biomedical Research, Inc.$354,061,551
- Randall J Bateman · Washington University$187,292,085
- Paul S. Aisen · Cognition Therapeutics, Inc.$175,382,342
- Reisa A. Sperling · Banner Health$145,046,481
- Barton F Haynes · Duke University$136,029,850
- Joseph L Goldstein · University Of Texas Sw Med Ctr/Dallas$102,433,280
Research focus
ProteinsInsightMouse ModelMediatingCellsMessenger RnaFrontotemporal DementiaMutationNeurodegenerative DisordersBrainAffectGranulinNovel Therapeutic InterventionLightMrna DecayPgrn GeneBaseFibroblastsPeptide HydrolasesMutantAntibodiesPlasmaGenesMolecular
Grant awards (16)
Methods for treating aging-related cognitive decline and reducing risk of AD/ADRD by enhancing the endogenous expression of adropin$416,625
R21 · FY2024 · AG
Targeted Modulation of Longevity-Associated Genes Using Antisense Oligonucleotides$416,625
R21 · FY2024 · AG · contact PI
Antisense Oligonucleotides for Progranulin-deficient Frontotemporal Dementia$75,350
R56 · FY2024 · AG · contact PI
Antisense Oligonucleotides for Targeting Nonsense-mediated mRNA Decay in Frontotemporal Dementia$378,750
R01 · FY2023 · AG · contact PI
Antisense Oligonucleotides for Targeting Nonsense-mediated mRNA Decay in Frontotemporal Dementia$378,750
R01 · FY2022 · AG · contact PI
Antisense Oligonucleotides for Targeting Nonsense-mediated mRNA Decay in Frontotemporal Dementia$378,750
R01 · FY2021 · AG · contact PI
Antisense Oligonucleotides for Targeting Nonsense-mediated mRNA Decay in Frontotemporal Dementia$378,750
R01 · FY2020 · AG · contact PI
Mapping Progranulin's Bioactivity: Implications for Disease and Potential Therapies$235,803
R00 · FY2020 · AG · contact PI
Antisense Oligonucleotides for Targeting Nonsense-mediated mRNA Decay in Frontotemporal Dementia$375,403
R01 · FY2019 · AG · contact PI
Mapping Progranulin's Bioactivity: Implications for Disease and Potential Therapies$243,620
R00 · FY2019 · AG · contact PI
Mapping Progranulin's Bioactivity: Implications for Disease and Potential Therapies$249,000
R00 · FY2018 · AG · contact PI
Mapping Progranulin's Bioactivity: Implications for Disease and Potential Therapi$128,412
K99 · FY2015 · AG · contact PI
Mapping Progranulin's Bioactivity: Implications for Disease and Potential Therapi$128,412
K99 · FY2014 · AG · contact PI
Role of Progranulin in Mediating the Anti-Inflammatory Property of High-Density L$6,165
F32 · FY2014 · HL · contact PI
Role of Progranulin in Mediating the Anti-Inflammatory Property of High-Density L$55,670
F32 · FY2013 · HL · contact PI
Role of Progranulin in Mediating the Anti-Inflammatory Property of High-Density L$53,942
F32 · FY2012 · HL · contact PI